Investing.com – U.S. stocks were higher after the close on Monday, as gains in the Oil & Gas, Healthcare and Technology sectors led shares higher. At the close in NYSE, the Dow...
Investing.com – Wall Street was mixed on Monday, as investors turned their focus to a highly-anticipated Federal Reserve meeting this week that is expected to pave the way...
By Tamara Mathias and Ankur Banerjee (Reuters) - Eli Lilly (N:LLY) said on Monday it will buy Loxo Oncology Inc (O:LOXO) for $8 billion, an expensive bet on a pipeline of cancer...
Pfizer, Inc. (NYSE:PFE) reported second-quarter 2019 adjusted earnings per share of 80 cents, which beat the Zacks Consensus Estimate of 77 cents. Earnings rose 4% year over...
Investor focus will be on any update that Array BioPharma Inc. (NASDAQ:ARRY) provides about its acquisition by Pfizer (NYSE:PFE) when it reports fourth-quarter fiscal 2019...
Pfizer, Inc. (NYSE:PFE) will report its second-quarter 2019 results on Jul 30, before market open. In the last reported quarter, the company delivered a positive earnings...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Technical Indicators||Strong Sell||Sell||Strong Buy||Strong Buy||BUY|
|Summary||Strong Sell||Neutral||Strong Buy||Strong Buy||Buy|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Engulfing Bearish||1M||3||Apr 19|
|Engulfing Bearish||1H||7||Jul 26, 2019 03:00PM|
|Engulfing Bearish||5H||10||Jul 22, 2019 03:00PM|
|Evening Doji Star||1M||12||Jul 18|
|Falling Three Methods||1M||12||Jul 18|
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.Read More
|Securities Investor Protection Corporation (United States)||$0||Start Trading|
|National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States)||$500||Start Trading|
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.